Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300–2306.

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., … Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47–55.

CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., … Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279–85.

Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., … Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321–31.

Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient: a case report and review of the literature
Cha, S., Johnston, L., Natkunam, Y., & Brown, J. (2005). Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient: a case report and review of the literature. TRANSPLANT INFECTIOUS DISEASE, 7(3-4), 158–61.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703–11.

Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity
Johnston, L. (2008). Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 21(2), 177–92.

High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience
Agarwal, R., Dvorak, C. C., Stockerl-Goldstein, K. E., Johnston, L., & Srinivas, S. (2009). High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. BONE MARROW TRANSPLANTATION, 43(7), 547–552.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., … Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303–9.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99.

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen
Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M., … Brown, J. M. (2011). Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(5), 693–702.

Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination
Sales, C. S., Johnston, L. J., & Ta, C. N. (2011). Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination. CORNEA, 30(2), 143–49.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87.

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
Mueller, A. M. S., Kohrt, H. E. K., Cha, S., Laport, G., Klein, J., Guardino, A. E., … Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125–33.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–78.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54.

Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma
Minn, A. Y., Riedel, E., Halpern, J., Johnston, L. J., Horning, S. J., Hoppe, R. T., & Goodman, K. A. (2012). Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 159(3), 329–39.

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma;
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma; (2003). Blood, 2003.

Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial
Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., … Confer, D. L. (2011). Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. BLOOD. SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., … Confer, D. L. (2012). Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. NEW ENGLAND JOURNAL OF MEDICINE, 367(16), 1487–96.

A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. B., Arai, S., Johnston, L., … Miklos, D. B. (2011). A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. BLOOD, 118(21), 866–67.

Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation.
Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Goldstein, K., Johnston, L. J., … Negrin, R. S. (2006). Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation. BLOOD, 108(11), 126A–126A.

A Phase 1 Open Label, Multi-Center, Dose Escalation Study of Nilotinib (NLT) in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease (cGvHD)
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T., Arai, S., Johnston, L., … Miklos, D. B. (2013). A Phase 1 Open Label, Multi-Center, Dose Escalation Study of Nilotinib (NLT) in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease (cGvHD). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. SALT LAKE CITY,UT,UT,UT,UT,UT,UT: ELSEVIER SCIENCE INC.

Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse.
Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K., … Strober, S. (2003). Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse. BLOOD, 102(11), 152A–153A.

Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.
Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos, D., … Horning, S. (2008). Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma. BLOOD, 112(11), 765–66.

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J., Cheng, E. C., McMillan, A., … Miklos, D. (2009). A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis. BLOOD. NEW ORLEANS,LA,LA,LA,LA,LA,LA,LA,LA: AMER SOC HEMATOLOGY.

Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Coram, M., McMillan, A., … Miklos, D. (2010). Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development. BLOOD, 116(21), 958–58.

Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation
Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, G. G., … Lowsky, R. (2013). Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S154–S155.

TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN
Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnston, L., … Lowsky, R. (2013). TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S113–S114.

High dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience.
Cao, T. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., Taylor, T. L., Shizuru, J. A., … Stockerl-Goldstein, K. E. (2000). High dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BLOOD, 96(11), 482A–482A.

Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy
Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R., … Negrin, R. (2007). Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy. BLOOD, 110(11), 179A–179A.

Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose.
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2004). Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose. BLOOD, 104(11), 56A–56A.

Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd
Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., Strober, S., … Miklos, D. (2008). Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd. BLOOD. SAN FRANCISCO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.

Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., Johnston, L., … Lowsky, R. (2012). Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. BLOOD, 120(21).

Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD.
Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., … Miklos, D. (2006). Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.

Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (AHCT) using the Ceprate SC stem cell concentration system for multiple myeloma (MM).
Stockerl-Goldstein, K. E., Brown, J. M., O'Brien, R. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., … Blume, K. G. (1999). Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (AHCT) using the Ceprate SC stem cell concentration system for multiple myeloma (MM). BLOOD, 94(10), 608A–608A.

Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity.
Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., Shizuru, J., … Strober, S. (2006). Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity. BLOOD, 108(11), 182A–182A.

Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications.
Horwitz, S. M., Breslin, S., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., … Horning, S. J. (2000). Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications. BLOOD, 96(11), 384A–384A.

High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma.
Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Sheehan, K., Shizuru, J. A., … Lowsky, R. (2006). High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma. BLOOD, 108(11), 462B–463B.

Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas.
Horwitz, S. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Stuart, M. J., … Horning, S. J. (2001). Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas. BLOOD, 98(11), 862A–862A.

Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen
Schaenman, J., Vana, M. L., Rhee, C., Wong, J., Navato, S., Johnston, L. J., … Brown, J. (W. (2008). Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen. BLOOD. SAN FRANCISCO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.

Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia
Rose, J. A., Dunn, T. J., Liedtke, M., Elson, P., Kalaycio, M., Copelan, E., … Advani, A. (2012). Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia. BLOOD, 120(21).

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
Martin, P. J., Storer, B. E., Rowley, S. D., Flowers, M. E. D., Lee, S. J., Carpenter, P. A., … Weisdorf, D. (2009). Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. BLOOD, 113(21), 5074–82.

Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD
Lee, S. J., Flowers, M. E. D., Martin, P. J., Carpenter, P., Hansen, J., Chai, X., … Schultz, K. (2011). Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(8), 1114–20.

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A., Cummings, C. C., … Radich, J. P. (2007). The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. BLOOD, 109(4), 1782–89.

So you want to build a Web site + A blueprint for museum professionals
Johnston, L., & JONESGARMIL, K. (1997). So you want to build a Web site + A blueprint for museum professionals. MUSEUM NEWS, 76(1), 41–44.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43.

Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management
Jim, H. S. L., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., Nelson, A. M., … Palesh, O. (2014). Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(10), 1465–84.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Cutler, C., Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., … Antin, J. H. (2014). Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. BLOOD, 124(8), 1372–77.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report
Carpenter, P. A., Kitko, C. L., Elad, S., Flowers, M. E. D., Gea-Banacloche, J. C., Halter, J. P., … Couriel, D. R. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(7), 1167–87.

Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management.
Jim, H. S. L., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., Nelson, A. M., … Palesh, O. (2014). Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management. Biology of Blood and Marrow Transplantation , 20(10), 1465–84.

Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation
Tierney, D. K., Palesh, O., & Johnston, L. (2015). Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation. ONCOLOGY NURSING FORUM, 42(5), 488–97.

Intensive Care Utilization for Hematopoietic Cell Transplant Recipients
Jenkins, P., Johnston, L. J., Pickham, D., Chang, B., Rizk, N., & Tierney, D. K. (2015). Intensive Care Utilization for Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(11), 2023–27.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
Williams, K. M., Cheng, G.-S., Pusic, I., Jagasia, M., Burns, L., Ho, V. T., … Lee, S. J. (2016). Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(4), 710–16.

Increased Foxp3(+)Helios(+) Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells
Chen, Y.-B., Efebera, Y. A., Johnston, L., Ball, E. D., Avigan, D., Lekakis, L. J., … Bui, J. D. (2017). Increased Foxp3(+)Helios(+) Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(4), 625–34.

Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57.

Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W.-K., … Lowsky, R. (2016). Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., … Meyer, E. (2015). Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. BLOOD. AMER SOC HEMATOLOGY.

Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90.

Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells
Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S145.

Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation
Scheiber, C., Johnston, L., Packer, M., Gevirtz, R., Edwards, K. S., & Palesh, O. (2018). Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation. Oncology Nursing Forum, 45(2), 250–59.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., … Chen, Y.-B. (2017). Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017758177.

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., … Miklos, D. B. (2018). Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(2), 373–80.

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)
Weng, W.-K., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Kim, Y. H. (2014). Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS). BLOOD, 124(21).

Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience
Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Weng, W.-K. (2014). Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48.

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors
Hashmi, S. K., Lee, S. J., Savani, B. N., Burns, L., Wingard, J. R., Perales, M.-A., … Carpenter, P. A. (2018). ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(6), 1119–24.

Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant
Cheng, G.-S., Storer, B., Chien, J. W., Jagasia, M., Hubbard, J. J., Burns, L., … Williams, K. M. (2016). Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. ANNALS OF THE AMERICAN THORACIC SOCIETY, 13(11), 1932–39.

BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial
Cheng, G.-S., Pusic, I., Jagasia, M. H., Burns, L. J., Ho, V. T., Pidala, J., … Williams, K. M. (2015). BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study
Jagasia, M. H., Chai, X., Pidala, J., Inamoto, Y., Arora, M., Cutler, C. S., … Lee, S. J. (2014). Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network
Carpenter, P. A., Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., … Arora, M. (2016). Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation
Williams, K. M., Cheng, G.-S., Pusic, I., Jagasia, M. H., Burns, L. J., Ho, V. T., … Lee, S. J. (2015). Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors
Spinner, M. A., Vina, M. F., Elder, L., Arai, S., Johnston, L., Meyer, E., … Rezvani, A. R. (2016). Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. BLOOD. AMER SOC HEMATOLOGY.

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., … Lowsky, R. (2016). Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801
Carpenter, P. A., Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., … Arora, M. (2018). A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. HAEMATOLOGICA, 103(11), 1915–24.

Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., … Hashmi, S. K. (2018). Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation.
Sauter, C. S., DeFilipp, Z., Inamoto, Y., Johnston, L., Nagler, A., Savani, B. N., … Perales, M.-A. (2018). ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial
Gooptu, M., Kim, H. T., Chen, Y.-B., Rybka, W., Artz, A., Boyer, M., … Soiffer, R. J. (2018). Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(11), 2216–23.

Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD, 132.

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Membranous glomerulonephritis and nephrotic syndrome as a late manifestation of chronic graft-versus-host reaction following allogeneic transplantation for hematologic malignancy.
Ahmad, B., Stehr, B., Johnston, L., Smith, E. P., Nademanee, A. P., Parker, P. M., … Forman, S. J. (2006). Membranous glomerulonephritis and nephrotic syndrome as a late manifestation of chronic graft-versus-host reaction following allogeneic transplantation for hematologic malignancy. BLOOD, 108(11), 819A–820A.

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Johnston, L., Armstrong, R., Baker, J., Sahaf, B., Otani, J., Tate, K., … Negrin, R. S. (2016). A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease. BLOOD. AMER SOC HEMATOLOGY.

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
Carpenter, P. A., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., … Anasetti, C. (2005). A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(6), 465–71.

Integrating cancer survivorship care into allogeneic BMT recovery.
Bugos, K., Stenger, S., Smith, A. S., Johnston, L., Gross, M., Knight, G., … Muffly, L. S. (2017). Integrating cancer survivorship care into allogeneic BMT recovery. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia
Carpenter, P. A., Johnston, L., Fernandez, H. F., Radich, J. P., Mauro, M. J., Flowers, M. E. D., … Gooley, T. A. (2017). Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. BLOOD, 130(9), 1170–72.

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)
Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., … Chen, Y.-B. (2016). A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). BLOOD, 128(22).

Central Nervous System Involvement of Chronic Graft Versus Host Disease
Neppalli, A. K., & Johnston, L. (2016). Central Nervous System Involvement of Chronic Graft Versus Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S407.

A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD.
Carpenter, P., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., … Anasetti, C. (2003). A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD. BLOOD, 102(11), 712A.

A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF.
Nash, R. A., Johnston, L., Parker, P. M., Slattery, J. T., Storer, B., Furlong, T., … Storb, R. (2003). A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF. BLOOD, 102(11), 240A.

A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph plus ) Leukemias
Carpenter, P. A., Johnston, L., Fernandez, H., Radich, J., Mauro, M. J., Flowers, M. E. D., … Gooley, T. (2015). A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph plus ) Leukemias. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(2), S274–S276.

Yield of Single versus Upper and Lower Endoscopic Biopsies in the Diagnosis of Gastrointestinal Graft-Versus-Host Disease in Patients with Prior Allogeneic Hematopoietic Stem Cell Transplantation
Liu, A., Meyer, E., Johnston, L., & Gerson, L. (2012). Yield of Single versus Upper and Lower Endoscopic Biopsies in the Diagnosis of Gastrointestinal Graft-Versus-Host Disease in Patients with Prior Allogeneic Hematopoietic Stem Cell Transplantation. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP.

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
Nash, R. A., Johnston, L., Parker, P., McCune, P. S., Storer, B., Slattery, J. T., … Storb, R. (2005). A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(7), 495–505.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Williams, K. M., Cheng, G.-S. S., Pusic, I., Jagasia, M., Burns, L., Ho, V. T., … Lee, S. J. (2016). Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 22(4), 710–716.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 4(10).

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., … Hashmi, S. K. (2019). Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10).

Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64.

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
DeFilipp, Z., Advani, A. S., Bachanova, V., Cassaday, R. D., Deangelo, D. J., Kebriaei, P., … Weisdorf, D. (2019). Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., … Hashmi, S. K. (2019). Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). BONE MARROW TRANSPLANTATION, 54(11), 1868–80.

HLA Class II Donor-Specific Antibody Desensitization with Nonleukoreduced Irradiated Whole Blood Pretransplant
Jacob, R., Tho Pham, Vina, M. F., Zhang, M., Johnston, L., Hussain, M., & Pandey, S. (2019). HLA Class II Donor-Specific Antibody Desensitization with Nonleukoreduced Irradiated Whole Blood Pretransplant. TRANSFUSION, 59, 94A.

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S106.

Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool
Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V. R., Bredeson, C., … Artz, A. S. (2020). Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S45–S46.

Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant.
Sharifi, H., Lai, Y. K., Guo, H., Hoppenfeld, M., Guenther, Z. D., Johnston, L., … Hsu, J. L. (2020). Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant. Chest.

Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation.

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82.

Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155.

Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy.

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy.

Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation.
Sharifi, H., Guenther, Z. D., Leung, A. N., Johnston, L., Lai, Y. K., Hsu, J. L., & Guo, H. H. (2021). Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation. Journal of Thoracic Imaging.

Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation.

Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine.

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
Kharfan-Dabaja, M. A., Kumar, A., Ayala, E., Aljurf, M., Nishihori, T., Marsh, R., … Carpenter, P. A. (2021). Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 27(8), 642–649.

Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151.

NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS.
Winge, M. C., Rieger, K. E., Kim, J., Weng, W.-K., Johnston, L. J., Miklos, D. B., … Kwong, B. Y. (2021). NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS. Journal of the American Academy of Dermatology.

Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances.

Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.